Has Zealand Pharma (CPSE:ZEAL) Fallen Enough To Look Cheap On Earnings?

Zealand Pharma shares have fallen sharply over the past year, which puts fresh focus on whether the current price still lines up with what the business earns. With sentiment swinging around new obesity and diabetes drugs, the key issue is how much of that story is already reflected in the earnings multiple today.

• The stock has declined 52.2% over the past 12 months, which raises the question of whether recent price weakness or the underlying earnings power is doing more of the heavy lifting in the valuation.

• Positive Phase 2 results for petrelintide and the move into a Phase 3 program with Roche may support expectations for future profitability. This can have a direct impact on how investors judge its current earnings-based valuation.

• There is a second opinion on Zealand Pharma worth weighing. See what analysts think Zealand Pharma's shares could be worth .

The issue now is whether Zealand Pharma's present share price is adequately explained by its earnings when set against the Fair Ratio benchmark.

If you want context for Zealand Pharma's earnings story, it helps to compare it with other healthcare names focused on similar themes using 127 healthcare AI stocks

Does Zealand Pharma Look Pricey on Earnings?

The P/E ratio works reasonably well for Zealand Pharma because earnings are the main input that investors are weighing against the obesity and diabetes pipeline story. On this metric, the stock trades on about 5.9x earnings, which is far lower than the wider Biotechs sector on roughly 24.6x and also well below the peer group average of about 44.4x.

The Fair Ratio model, which adjusts the P/E you might expect for Zealand Pharma based on its growth profile, margins, size and risk, points to a lower multiple than the market is currently paying, so the shares screen as overvalued even though they look cheap against simple benchmarks. Because the recent Phase 2 petrelintide data and the move into Phase 3 with Roche have sharpened focus on future obesity earnings, the gap between the headline low P/E and the Fair Ratio benchmark matters more for anyone weighing how much of that story is already in the price. Explore the numbers behind Zealand Pharma's P/E valuation .

The Zealand Pharma Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the P/E and Fair Ratio puzzle for Zealand Pharma leaves off by spelling out which combinations of future growth, profitability and earnings power would need to occur for the stock to be worth meaningfully more or less than it is today. Each Narrative ties a fair value estimate to a specific version of Zealand Pharma's potential catalysts and risks so you can track over time which storyline appears to be taking shape on the Community page.